GuidelineThe Medical journal of Australia2025
2024 Royal Australian College of General Practitioners and Healthy Bones Australia guideline for osteoporosis management and fracture prevention in postmenopausal women and men over 50 years of age.
Guideline in The Medical journal of Australia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Health and adverse events associated with extended oral bisphosphonates among postmenopausal women: a systematic review.The Journal of clinical endocrinology and metabolism · 2026Pooled it
- 2024 Royal Australian College of General Practitioners and Healthy Bones Australia guideline for osteoporosis management and fracture prevention in postmenopausal women and men over 50 years of age.The Medical journal of Australia · 2025Guideline
- Management of Osteoporosis in Parkinson's Disease: A Systematic Review of Clinical Practice Guidelines.Movement disorders clinical practice · 2025Pooled it
- Paraspinal muscle CT measurements in predicting subsequent fractures after percutaneous kyphoplasty in elderly women.North American Spine Society journal · 2026Article
- Surface-Engineered Phytochemical Nanomedicines for Postmenopausal Osteoporosis: Skeletal Targeting, Imaging-Supported Evaluation, and Therapeutic Performance.Pharmaceutics · 2026Review
- From Risk to Treatment: Clinical Updates in Osteoporosis Management.International journal of rheumatic diseases · 2026Article
- Mind the gap: Adherence to denosumab dosing and cessation guidelines in Australian residential aged care.British journal of clinical pharmacology · 2026Article
- Comparisons of phantom-based and phantomless QCT bone mineral density for predicting subsequent fractures.Bone & joint research · 2026Article
- Future Directions in Hypercalcemic and Normocalcemic Primary Hyperparathyroidism: FRAXplus for 10-Year Fracture Risk Assessment (A Retrospective Study).Life (Basel, Switzerland) · 2026Article
- Primary Care Physicians' Interactions With a Novel Web-Based Active Learning Tool (The Community Fracture Capture Learning Hub): Qualitative Analysis.JMIR formative research · 2026Article
- The effectiveness of bisphosphonates vs denosumab in people with dementia or frailty post hip fracture: a multi-database cohort study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Review
- Management of male osteoporosis in primary care: clinical approach and pharmacotherapy.Singapore medical journal · 2026Article
- Awareness, attitudes and practices for osteoporosis prevention among postmenopausal women: A mixed-method survey and DEXA correlation.Bioinformation · 2026Article
- Association between neutrophil percentage-to-albumin ratio and bone mineral density and prevalent osteoporosis in patients with type 2 diabetes mellitus.Frontiers in endocrinology · 2026Article
- Follow-on osteoporosis therapy after denosumab discontinuation among Medicare beneficiaries.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Equipping pharmacists to improve osteoporosis management for aged care residents: a pilot study.Journal of pharmaceutical policy and practice · 2026Article
- The Conundrum of Medical Fracture Prevention in Chronic Kidney Disease-Summary of the Evidence and Pragmatic Clinical Guidance.Journal of clinical medicine · 2025Review
- Implementing pharmacist-led home medicines reviews within fracture liaison services for better post-fracture care: a qualitative study of patient and practitioner experience.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionThis updated guideline replaces the previous Royal Australian College of General Practitioners and Osteoporosis Australia (now, Healthy Bones Australia) guideline from 2017. The accumulation of high quality evidence supporting improvements in clinical practice over the past five years, need for expert consensus and opinion, and new developments in pharmacological management of osteoporosis, especially the role of osteoanabolic therapies, prompted this update. The aim was to provide clear, evidence-based recommendations to assist Australian general practitioners in managing patients over 50 years of age with poor bone health. However, it is useful for any health care professional caring for people with poor bone health and for health administrators and bureaucrats responsible for resource provision and allocation. MAIN RECOMMENDATIONS: Earlier recognition of poor bone health using clinical risk factors, and use of an absolute fracture risk assessment tool, particularly FRAX (https://fraxplus.org/), is encouraged. Widespread population-based osteoporosis screening is not recommended in Australia due to lack of supporting evidence. It is important to recognise patients with "imminent" or "very high" fracture risk, as this is a group in whom to consider early osteoanabolic therapy. Calcium and vitamin D supplementation are more effective in reducing fracture risk when given to individuals who have calcium and vitamin D deficiency (not to healthy non-institutionalised individuals). CHANGES IN ASSESSMENT AND MANAGEMENT AS A RESULT OF THE GUIDELINE: This guideline provides recommendations for the use of fracture risk assessment tools, particularly FRAX, for risk stratification, addresses the risk of rebound vertebral fracture following denosumab cessation, discusses removal of strontium as a therapy, clarifies "imminent" or "very high" fracture risk in patients and highlights the importance of calcium and vitamin D status, and the early use of osteoanabolic therapies. The full guideline is freely available at https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/osteoporosis/executive-summary.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.